

# Glossary

## Terms Related to Chugai's Business

### Unmet medical need

Medical need that is not adequately met due to a lack of effective treatments.

### First-in-class

An original drug that is highly novel and useful, and will significantly change the therapeutic system.

### Best-in-class

A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target.

### Development pipeline

At pharmaceutical companies, refers to drug candidates that are being developed.

### Proof of Concept (PoC)/Early PoC

Proof of concept (PoC) is confirmation that the therapeutic effect conceived in the research stage is effective in humans. Early PoC means that in addition to safety, signs of efficacy or pharmacological effect have been confirmed in a limited number of cases.

### Clinical trial

A study to verify the safety, efficacy and other characteristics of a drug in human subjects. Studies conducted for the purpose of filing an application for approval are called clinical trials.

**Phase I:** Performed on a small number of healthy volunteers (or, for certain disease areas and diseases, on patients) to assess the drug's safety and the process by which it is absorbed, distributed, metabolized and eliminated by the body.

**Phase II:** Performed on a small number of consenting patients to determine the safest and most effective dosage and the dosing regimen.

**Phase III:** Performed on a large number of consenting patients to verify the efficacy and safety of the new drug in comparison with existing drugs or placebo.

**Phase IV:** Post-marketing clinical surveillance. Performed on a larger number of consenting patients than in phase III studies to verify the drug's safety and efficacy for its approved indication(s).

### Application for approval

An application submitted by a pharmaceutical company to a regulatory agency to obtain approval for manufacturing and marketing of a new drug after its efficacy and safety have been verified in clinical trials. In Japan, the Minister of Health, Labour and Welfare (MHLW) grants manufacturing and marketing approval to substances deemed appropriate as pharmaceuticals based on reviews by the Pharmaceutical Affairs and Medical Devices Agency as well as academic and other experts in the Pharmaceutical Affairs and Food Sanitation Council.

### Additional indication

A new indication for a previously approved drug.

### Lifecycle management

The various measures taken to maximize the potential value of a drug, including shortening development time, expanding sales, extending the product's life, and conducting appropriate cost control.

## Terms Related to Drug Discovery

### Personalized Healthcare

Even when a particular disease is treated with the same drug, there may be differences in the efficacy and side effects of that drug depending on the patient. One of the causes is thought to be that the genetic information related to the disease is different in each patient. Personalized healthcare (PHC) is an approach that focuses on these genetic-level differences to provide treatment tailored to the characteristics of each patient's disease. It therefore brings significant benefits in term of efficiency, safety and cost effectiveness.

### Cancer Genomic Medicine

One example of personalized healthcare. Medical treatment that measures multiple cancer-related genes in a single operation using gene panel examination and performs optimal treatment according to each patient's genomic profile.

### Biopharmaceuticals

Drugs created by applying biotechnology such as genetic recombination. In the 1980s, when rapid advances were made in genetic engineering, Chugai decided to shift to research and development of biopharmaceuticals and made related large-scale capital investments.

### Therapeutic antibody

A type of biopharmaceutical, it is an artificially created antibody used as a medicine to prevent or treat diseases. Therapeutic antibodies are designed to act only on the specific molecule (antigen) that causes the disease, and therefore can be expected to provide high therapeutic efficacy and reduce side effects. Chugai launched the first therapeutic antibody created in Japan in 2005, and is leading the world with its proprietary antibody engineering technologies.

### Modality

In the pharmaceutical industry, refers to the material classification of a medicine. Until the 1990s, small molecule drugs were virtually the only modality, but the options are now increasing. New modalities enable new approaches to diseases that have no effective treatment methods. Chugai is focusing on establishing middle molecules as a third modality, in addition to its biologics and small molecules.

### Open innovation

Generating innovative value by utilizing the technologies and development capabilities of external research networks such as with universities, research institutions and other organizations.

### Translational Research

Research that builds a bridge between the findings of basic research by academia and the development of new medicines by pharmaceutical companies.

## Terms Related to Human Resources

### Work-life synergy (Work-life balance)

Chugai's work-life synergy aims to generate a synergistic effect that brings forth motivation, vitality and innovation by enhancing both work and the lives of individuals. Work-life synergy, an advancement of the concept of work-life balance, is necessary for a fulfilling personal life, as well as for becoming the top innovator in the healthcare industry.

## Diversity and Inclusion

At Chugai, diversity refers to a diversity of attributes such as gender, age and nationality, as well as ways of thinking, values and experience. Inclusion refers to the state of respecting each other's differences and the ability of everyone to contribute and perform at his or her full potential. When people with various backgrounds work together, they become aware of diverse perspectives and ideas. Companies promote diversity to create new value, which leads to innovation. Using this awareness for business innovation, companies promote diversity to create better-quality products and services. Also called "diversity and inclusion (D&I)," which refers to receptivity to diversity and incorporating diverse opinions and ideas rather than the simple pursuit of variety, and also encompasses the concept of raising organizational value.

## Talent management

Talent management is the human resource strategy by which we identify and develop leaders and highly skilled specialists at an early stage. It is also the means by which we improve the skills and enhance the motivation of employees throughout the Company, with the aim of realizing our corporate strategy and catalyzing the creation of innovation. Each organization at Chugai has formulated a long-term human resource development plan and is building a talent pool of leaders.

## Terms Related to the Roche Group

### Roche

A pharmaceutical company established in 1896 and headquartered in Basel, Switzerland. With business operations in more than 100 countries, the Roche Group contributes to medicine in a wide range of fields through its two business segments: pharmaceuticals and diagnostics. Central to the Roche Group's strategy is personalized healthcare, the approach of selecting the most appropriate treatment by using biomarkers and diagnostic tests to identify patients most likely to show a significant response to a particular drug. The Roche Group's sales in 2018 were 56.8 billion Swiss francs.

### Roche Diagnostics K.K.

The Japanese subsidiary of the Roche Group's diagnostics division. Established in 1998, Roche Diagnostics K.K. provides a wide range of innovative diagnostic solutions, including in-vitro diagnostics and diagnostic equipment and research reagents and related equipment.

### Genentech Inc.

A leading biotechnology company headquartered in South San Francisco, California. Genentech has been a member of the Roche Group since 1990.

### Foundation Medicine Inc. (FMI)

FMI was established in Massachusetts, U.S.A. in 2010. In 2015, Roche took a majority stake, and then acquired the remaining outstanding shares in 2018 to make FMI a wholly-owned subsidiary. Chugai established the FMI business as a specialized unit in October 2018 to carry out commercialization and product value maximization of FMI's "Comprehensive Genomic Profiling Service" in Japan.

# Network

(As of April 1, 2019)

## Chugai Pharmaceutical

### Head Office

Nihonbashi Mitsui Tower (Reception 15F)  
2-1-1 Nihonbashi-Muromachi,  
Chuo-ku, Tokyo 103-8324 Japan  
Tel +81-(0)3-3281-6611 (main switchboard)  
URL: <https://www.chugai-pharm.co.jp/english/>

### Research Laboratories

#### Fuji Gotemba Research Laboratories

1-135 Komakado, Gotemba City,  
Shizuoka Pref. 412-8513 Japan  
Tel +81-(0)550-87-3411

#### Kamakura Research Laboratories

200 Kajiwara, Kamakura City,  
Kanagawa Pref. 247-8530 Japan  
Tel +81-(0)467-47-2260

#### Ukima Research Laboratories

5-5-1 Ukima, Kita-ku,  
Tokyo 115-8543 Japan  
Tel +81-(0)3-3968-6111

### Plants

#### (Chugai Pharma Manufacturing Co., Ltd.)

#### Ukima Plant

5-5-1 Ukima, Kita-ku, Tokyo 115-8543 Japan  
Tel +81-(0)3-3968-6200

#### Fujieda Plant

2500 Takayanagi, Fujieda City,  
Shizuoka Pref. 426-0041 Japan  
Tel +81-(0)54-635-2311

#### Utsunomiya Plant

16-3 Kiyohara-Kogyodanchi, Utsunomiya City,  
Tochigi Pref. 321-3231 Japan  
Tel +81-(0)28-667-7611

### Branches

#### Hokkaido Branch

8F Nihon Seimei Sapporo Bldg., 4-1-1  
Kita-sanjo-Nishi, Chuo-ku, Sapporo City,  
Hokkaido 060-0003 Japan  
Tel +81-(0)11-271-5311

#### Miyagi and Yamagata Branch

3F Sankyo Sendai Bldg., 1-12-7 Honcho,  
Aoba-ku, Sendai City,  
Miyagi Pref. 980-0014 Japan  
Tel +81-(0)22-225-8551

#### Kita-Tohoku Branch

##### (Iwate/Aomori/Akita)

5F Higashi-nihon Fudousan Morioka Ekimae  
Bldg., 15-20 Morioka-ekimae-dori, Morioka City,  
Iwate Pref. 020-0034 Japan  
Tel +81-(0)19-625-2811

#### Fukushima Branch

17F Big-i, 2-11-1 Kouriyamashi Ekimae,  
Fukushima Pref. 963-8002 Japan  
Tel +81-(0)24-933-6303

#### Saitama Branch

8F Omiya Center Bldg., 1-9-6 Sakuragicho,  
Omiya-ku, Saitama City,  
Saitama Pref. 330-0854 Japan  
Tel +81-(0)48-642-4771

#### Ibaraki Branch

8F Nissei Mito Bldg., 2-2-27 Izumi-cho,  
Mito City, Ibaraki Pref. 310-0026 Japan  
Tel +81-(0)29-227-1951

#### Gunma and Tochigi Branch

9F East Tower, 16-11 Sakae-cho,  
Takasaki City, Gunma Pref. 370-0841 Japan  
Tel +81-(0)27-321-6511

#### Niigata Branch

9F Niigata Ekimae Bldg., 3-2-3 Benten,  
Chuo-ku, Niigata City,  
Niigata Pref. 950-0901 Japan  
Tel +81-(0)25-247-7331

#### Nagano and Yamanashi Branch

8F Kenshin Matsumoto Fukashi Bldg.,  
2-5-2 Fukashi, Matsumoto City,  
Nagano Pref. 390-0815 Japan  
Tel +81-(0)263-34-1373

#### Tokyo Branch 1

#### Tokyo Branch 2

#### Tokyo Branch 3

17F Osaki Bright Core Bldg.,  
5-5-15 Kita-shinagawa, Shinagawa-ku,  
Tokyo 141-0001 Japan  
Tel +81-(0)3-5449-6760

#### Tokyo Tama Branch

6F Tachikawa Nishiki-cho Bldg.,  
1-8-7 Nishiki-cho, Tachikawa City,  
Tokyo 190-0022 Japan  
Tel +81-(0)42-523-6661

#### Chiba Branch

5F Fujimi Hainesu Bldg., 2-7-5 Fujimi, Chuo-ku,  
Chiba City, Chiba Pref. 260-0015 Japan  
Tel +81-(0)43-224-1511

#### Yokohama Branch

3F Yokohama East Square, 1-4 Kinkou-cho,  
Kanagawa-ku, Yokohama City,  
Kanagawa Pref. 221-0056 Japan  
Tel +81-(0)45-450-7670

#### Atsugi Branch

8F Nihon Seimei Hon-atsugi Bldg.,  
1-2-1 Asahi-cho, Atsugi City,  
Kanagawa Pref., 243-0014 Japan  
Tel +81-(0)46-229-2700

#### Aichi Branch

KDX Sakura-dori Bldg., 3-20-17  
Marunouchi, Naka-ku, Nagoya City,  
Aichi Pref. 460-0002 Japan  
Tel +81-(0)52-961-8511

#### Gifu and Mie Branch

11F Nouhi Nissei Bldg., 2-8 Hashimoto-cho, Gifu  
City, Gifu Pref. 500-8856 Japan  
Tel +81-(0)58-252-7400

#### Shizuoka Branch

4F Nissei Shizuoka Ekimae Bldg.,  
59-7 Kurogane-cho, Aoi-ku, Shizuoka City,  
Shizuoka Pref. 420-0851 Japan  
Tel +81-(0)54-252-5125

#### Kyoto and Shiga Branch

7F Karasuma Chuo Bldg., 659 Tearaimizu-cho,  
Nishikikoji-agaru, Karasuma-dori, Nakagyo-ku,  
Kyoto City, Kyoto 604-8152 Japan  
Tel +81-(0)75-212-6090

#### Hokuriku Branch

##### (Ishikawa/Toyama/Fukui)

13F Visage, 16-1 Showa-cho, Kanazawa City,  
Ishikawa Pref. 920-0856 Japan  
Tel +81-(0)76-232-6766

#### Osaka-Kita Branch

13F Uemura Nissei Bldg.,  
3-3-31 Miyahara, Yodogawa-ku,  
Osaka City, Osaka 532-0003 Japan  
Tel +81-(0)6-6350-6355

#### Osaka-Minami Branch

14F Portas Center Bldg.,  
4-45-1 Ebisuji-machi, Sakae-ku,  
Sakae City, Osaka 590-0985 Japan  
Tel +81-(0)72-223-1575

#### Nara and Wakayama Branch

5F Nara Center Bldg., 7-1-33 Omiya-cho,  
Nara City, Nara Pref. 630-8115 Japan  
Tel +81-(0)742-33-6011

#### Hyogo Branch

9F Meiji Yasuda Seimei Kobe Bldg.,  
8-3-5 Isogami-dori, Chuo-ku, Kobe City,  
Hyogo Pref. 651-0086 Japan  
Tel +81-(0)78-241-6851

#### Hiroshima Branch

6F Nissei Hiroshima Bldg.,  
7-32 Nakamachi, Naka-ku, Hiroshima City,  
Hiroshima Pref. 730-0037 Japan  
Tel +81-(0)82-543-6100

#### Yamaguchi Branch

10F Square Shin-yamaguchi,  
2-21 Ogori-kogane-machi, Yamaguchi City,  
Yamaguchi Pref. 754-0021 Japan  
Tel +81-(0)83-972-1666

#### Tottori and Shimane Branch

6F Yonago Shoko Kaigisho Kaikan,  
2-204 Kamo-cho, Yonago City,  
Tottori Pref. 683-0823 Japan  
Tel +81-(0)859-34-3521

#### Okayama Branch

4F Lit City Bldg., 15-1 Ekimoto-machi, Kita-ku,  
Okayama City, Okayama Pref. 700-0024 Japan  
Tel +81-(0)86-214-3760

#### Kagawa and Tokushima Branch

7F Ichigo Takamatsu Bldg.,  
2-2-7 Kotobuki-cho, Takamatsu City,  
Kagawa Pref. 760-0023 Japan  
Tel +81-(0)87-811-6988

#### Ehime and Kouchi Branch

8F Taijyu Seimei Matsuyama Bldg.,  
4-1-1 Ichiban-cho, Matsuyama City,  
Ehime Pref. 790-0001 Japan  
Tel +81-(0)89-945-3600

#### Fukuoka Branch

8F Echo Bldg., 2-13-34 Hakataeki-higashi,  
Hakata-ku, Fukuoka City,  
Fukuoka Pref. 812-0013 Japan  
Tel +81-(0)92-451-8181

#### Nagasaki and Saga Branch

Nagasaki Ekimae Daiichi Seimei Bldg.,  
2-3 Nishizaka-machi, Nagasaki City,  
Nagasaki Pref. 850-0051  
Tel +81-(0)95-825-4772

**Kumamoto and Oita Branch**

2F Ichigo Kumamoto Bldg., 6-7 Karashima-cho,  
Chuo-ku, Kumamoto City,  
Kumamoto Pref. 860-0804 Japan  
Tel +81-(0)96-359-6311

**Kagoshima and Miyazaki Branch**

7F KSC Kamoike Bldg., 2-4-35 Yojiro,  
Kagoshima City,  
Kagoshima Pref. 890-0062 Japan  
Tel +81-(0)99-251-1600

**Okinawa Branch**

11F JPR Naha Bldg.,  
1-1-19 Matsuyama, Naha City,  
Okinawa Pref. 900-0032 Japan  
Tel +81-(0)98-861-1211

**Regional Management Offices (RMO)****Domestic****Hokkaido and Tohoku RMO**

3F Sankyo Sendai Bldg., 1-12-7 Honcho,  
Aoba-ku, Sendai City,  
Miyagi Pref. 980-0014 Japan  
Tel +81-(0)22-225-8551

**Kanto-Kita and Koshinetsu RMO**

8F Omiya Center Bldg., 1-9-6 Sakuragicho,  
Omiya-ku, Saitama City,  
Saitama Pref. 330-0854 Japan  
Tel +81-(0)48-642-4771

**Kanto-Minami RMO**

17F Osaki Bright Core Bldg.,  
5-5-15 Kita-shinagawa, Shinagawa-ku,  
Tokyo 141-0001 Japan  
Tel +81-(0)3-5449-6760

**Tokai and Hokuriku RMO**

KDX Sakura-dori Bldg., 3-20-17 Marunouchi,  
Naka-ku, Nagoya City,  
Aichi Pref. 460-0002 Japan  
Tel +81-(0)52-961-8511

**Kansai RMO**

13F Uemura Nissei Bldg., 3-3-31 Miyahara,  
Yodogawa-ku, Osaka City,  
Osaka 532-0003 Japan  
Tel +81-(0)6-6350-6355

**Chugoku and Shikoku RMO**

6F Nissei Hiroshima Bldg., 7-32 Nakamachi,  
Naka-ku, Hiroshima City,  
Hiroshima Pref. 730-0037 Japan  
Tel +81-(0)82-543-6100

**Kyushu RMO**

8F Echo Bldg., 2-13-34 Hakataeki-higashi,  
Hakata-ku, Fukuoka City,  
Fukuoka Pref. 812-0013 Japan  
Tel +81-(0)92-451-8181

**Domestic Subsidiaries****Chugai Clinical Research Center Co., Ltd.**

2-1-1 Nihonbashi-Muromachi,  
Chuo-ku, Tokyo 103-8324 Japan  
(within the Chugai Pharmaceutical Head Office)  
Tel+81-(0)3-3273-1173

**Chugai Research Institute  
for Medical Science, Inc.**

1-135 Komakado, Gotemba City,  
Shizuoka Pref. 412-8513 Japan  
(within the Fuji Gotemba Research Laboratories)  
Tel +81-(0)550-87-5425

**Chugai Business Support Co., Ltd.**

5-5-1 Ukima, Kita-ku,  
Tokyo 115-8543 Japan  
(within the Ukima Representative Office)  
Tel +81-(0)3-3968-8760

**Medical Culture Inc.**

Muromachi CS Bldg.,  
4-6-5 Nihonbashi-Muromachi,  
Chuo-ku, Tokyo 103-0022 Japan  
Tel +81-(0)3-5202-8270

**Chugai Distribution Co., Ltd.**

1-20, Okuwa, Kazo City,  
Saitama Pref. 347-0010 Japan  
(within the Kazo Distribution Center)  
Tel +81-(0)480-76-0381

**Chugai Pharma Manufacturing Co., Ltd.**

5-5-1 Ukima, Kita-ku,  
Tokyo 115-8543 Japan  
(within the Ukima Representative Office)  
Tel +81-(0)3-3968-6200

**Forerunner Pharma Research Co., Ltd.**

Komaba Open Laboratory, The University  
of Tokyo, 4-6-1 Komaba, Meguro-ku,  
Tokyo 153-8904 Japan  
Tel +81-(0)3-5452-5726

**Overseas Subsidiaries,  
Affiliates and R&D Partners****Europe****Chugai Pharma U.K. Ltd.**

Mulliner House, Flanders Road,  
Turnham Green, London W4 1NN U.K.  
Tel +44-(0)20-8987-5680

**Chugai Pharma Europe Ltd.**

Mulliner House, Flanders Road,  
Turnham Green, London W4 1NN U.K.  
Tel +44-(0)20-8987-5600

**Chugai Pharma Germany GmbH**

Lyoner Strasse 15, 60528  
Frankfurt am Main, Germany  
Tel +49-(0)69-663000-0

**Chugai Pharma France SAS**

Tour Franklin, La Défense 8,  
100/101 Quartier Boieldieu,  
92042 Paris La Défense cedex, France  
Tel +33-(0)1-56-37-05-20

**Chugai Pharma Europe Logistics S.A.S.**

Tour Franklin, Arche Sud,  
100/101 Quartier Boieldieu,  
92042 Paris La Défense cedex, France  
Tel: +33-(0)1-56-37-05-20

**United States****Chugai Pharma USA, Inc.**

300 Connell Drive, Suite 3100  
Berkeley Heights, NJ 07922 U.S.A.  
Tel +1-908-516-1350

**Asia****Chugai Pharma China Co., Ltd.**

Building G31, No. 801 Jiankang Dadao,  
Medical City, Taizhou, Jiangsu 225300 China  
Tel +86-(0)523-8681-9823

**Shanghai Branch**

Unit 2901, Central Plaza,  
No. 381 Central Huaihai Road,  
Shanghai 200020 China  
Tel +86-(0)21-6319-0388

**Beijing Branch**

1118 Beijing Fortune Bldg.  
No. 5, Dong San Huan Bei Lu,  
Chao Yang District,  
Beijing 100004, China  
Tel +86-(0)10-6590-8066

**Guangzhou Branch**

Unit 1508, Pearl River Tower, No. 15,  
Zhujiang West Road,  
Guangzhou 510623 China  
Tel +86-(0)20-8363-3468

**Chugai Pharma Science (Beijing) Co., Ltd.**

1108 Beijing Fortune Bldg.  
No. 5, Dong San Huan Bei Lu,  
Chao Yang District, Beijing 100004, China  
Tel +86-(0)10-6590-9556

**Chugai Pharma Taiwan Ltd.**

3F., No. 260, Dunhua N. Rd., Songshan District,  
Taipei 10548 Taiwan, R.O.C.  
Tel +886-(0)2-2715-2000

**Chugai Pharmabody Research Pte. Ltd.**

3 Biopolis Drive, #07-11 to 16 Synapse,  
Singapore 138623  
Tel +65-(0)6933-4888

**C&C Research Laboratories**

DRC, Sungkyunkwan University, 2066,  
Seobu-ro, Jangan-gu, Suwon-si, Gyeonggi-do  
16419 Korea  
Tel +82-(0)31-8014-6606

**Discovery Research Center**

DRC, Sungkyunkwan University, 2066,  
Seobu-ro, Jangan-gu, Suwon-si,  
Gyeonggi-do 16419 Korea  
Tel +82-(0)31-8014-6606

**Clinical Research Center**

#903 E&C Venture Dream Tower 3, 38-21,  
Digital-ro 31-gil, Guro-gu,  
Seoul 08376 Korea  
Tel +82-(0)2-858-6226

# Shareholder Information (As of December 31, 2018)

## Major Shareholders


Name	Number of Shares Held (Thousands)	Percentage of Voting Rights (%)
Roche Holding Ltd	335,223	61.27
The Master Trust Bank of Japan, Ltd. (Trust Account)	29,342	5.36
Japan Trustee Services Bank, Ltd. (Trust Account)	16,320	2.98
STATE STREET BANK AND TRUST COMPANY 505001	15,614	2.85
JP MORGAN CHASE BANK 380055	13,924	2.54
STATE STREET BANK WEST CLIENT - TREATY 505234	4,231	0.77
Japan Trustee Services Bank, Ltd. (Trust Account 5)	4,091	0.74
Trust & Custody Services Bank, Ltd. (Securities Investment Trust Account)	3,829	0.70
Japan Trustee Services Bank, Ltd. (Trust Account 7)	3,748	0.68
SSBTC CLIENT OMNIBUS ACCOUNT	3,651	0.66

Note: 12,459,413 shares of treasury stock held by the Company are not included in the above breakdown of major shareholders.


## Stock Price Information (From January 1, 2018 to December 31, 2018)

	Stock Price	
	Low	High
First Quarter	¥5,080	¥6,080
Second Quarter	5,310	6,210
Third Quarter	5,430	7,370
Fourth Quarter	6,230	7,850

## Classification of Shareholders



## Share Performance<sup>1</sup> with Stock Indices




1. Closing price on December 30, 2013 = 100

2. A capitalization-weighted index that consists of pharmaceutical companies on the Tokyo Stock Exchange, First Section.

## Share Price Indicators


### Price/Earnings Ratio

Year-end share price/Basic net income per share




### Price/Book Ratio

Year-end share price/Equity per share attributable to Chugai shareholders



### Dividend Yield

Dividends per share/Year-end share price



# Corporate Overview (As of December 31, 2018)

## Company Name

Chugai Pharmaceutical Co., Ltd.

## Year of Foundation

1925

## Year of Establishment

1943

## Address

2-1-1, Nihonbashi-Muromachi, Chuo-ku,  
Tokyo 103-8324 Japan

## Stated Capital

¥73,202 million

## Number of Employees

7,432 (Consolidated)

## Number of Shares Issued of Common Stock

559,685,889

## Number of Shareholders

19,947

## Stock Listing

Tokyo Stock Exchange, First Section

## Fiscal Year-End

December 31

## General Meeting of Shareholders

March

## Transfer Agent

Mitsubishi UFJ Trust and Banking Corporation

## Public Notices

Public notices are made electronically on the Chugai website (<https://www.chugai-pharm.co.jp/ir/>) in Japanese. In case electronic communications are unavailable, public notices will be made in the newspaper *Nihon Keizai Shimbun*.

## For further information, please contact:

Corporate Communications Dept.


Tel: +81-(0)3-3273-3313

Fax: +81-(0)3-3281-6607

E-mail: [ir@chugai-pharm.co.jp](mailto:ir@chugai-pharm.co.jp)


## IR website

<https://www.chugai-pharm.co.jp/english/ir/>



## Sustainability website


<https://www.chugai-pharm.co.jp/english/csr/>



Innovation all for the patients



**CHUGAI PHARMACEUTICAL CO., LTD.**

 A member of the Roche group